The overall goal of this research is to prepare a more stable and biocompatible CMOF through folic acid modification, and use it as a novel platform for the treatment of ischemic diseases. We have successfully synthesized CMOF-FA and demonstrated that CMOF-FA had a higher stability and lower cytotoxicity compared to CMOF. To further achieve this goal, we need to assess the angiogenic activity of CMOF-FA in vitro by scratch assay and tube formation assay. Also, we will generate a mouse hindlimb ischemic model to evaluate whether CMOF-FA is able to promote blood perfusion in ischemic tissue. During this postdoctoral training period, I will receive extensive training and mentorship in synthesis of CMOF based novel materials and using them as novel methods for the treatment of vascular diseases, which will mark an important step towards a scientific career as an independent researcher.
|Effective start/end date||1/1/16 → 12/31/17|
- American Heart Association Midwest Affiliate (16POST27710031)